GLP-1 Synergy Injections — $597 per month for all dosages, $547 per month on the 3-month bundle (Save $150 with a 3-month bundle).
GLP-1 Synergy is a physician-prescribed combination therapy that pairs compounded Semaglutide (GLP-1) and Tirzepatide (GIP/GLP-1) in a coordinated weekly injection protocol prepared by licensed U.S. 503A and 503B compounding pharmacies. By engaging both incretin pathways, Synergy is designed for patients whose physician determines that dual-pathway therapy best fits their individual clinical needs.
GLP-1 Synergy is a physician-prescribed combination of compounded Semaglutide (GLP-1 receptor agonist) and Tirzepatide (GIP/GLP-1 receptor agonist) prepared by licensed U.S. 503A or 503B compounding pharmacies. Your physician may prescribe this combination when they determine that targeting multiple incretin pathways best meets your individual clinical needs.
Your GOAL.MD physician evaluates your medical history, prior GLP-1 response, tolerability, and clinical goals to determine if dual-pathway combination therapy is appropriate for you. Synergy is typically considered for patients who have prior GLP-1 experience or whose physician determines that dual incretin coverage fits their plan.
Synergy is administered as a once-weekly subcutaneous injection — typically into the abdomen, thigh, or upper arm. Your physician customizes dosing on each component based on your response and tolerability. Each shipment includes detailed instructions, syringes, and alcohol swabs.
Single-agent Semaglutide engages the GLP-1 receptor only. Tirzepatide engages both GIP and GLP-1. Synergy combines both molecules so your physician has independent control over each pathway — useful for patients who plateaued on one agent or whose physician wants broader incretin coverage.
Patients on dual-incretin combination protocols often report deeper appetite suppression and longer satiety than with single-agent therapy. Individual results vary based on starting weight, adherence, dose, and lifestyle factors. Compounded combination products are not FDA-approved finished products and are not therapeutic equivalents of brand-name single-agent medications.
The most common side effects mirror those of single-agent GLP-1 therapy: nausea, diarrhea, constipation, decreased appetite, and mild fatigue — most appear during dose escalation and resolve within 1–2 weeks. Less common but more serious risks include pancreatitis, gallbladder issues, and (in animal studies) thyroid C-cell tumors. Discuss your full medical history with your physician.
You should not take Synergy if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also not recommended during pregnancy, while breastfeeding, or for patients with severe gastrointestinal disease, history of pancreatitis, or type 1 diabetes.
Pricing is the same regardless of dose adjustments to either component, so your monthly cost never goes up as your physician personalizes your protocol.
No. Unlike most telehealth providers, GOAL.MD doesn't auto-bill compounded programs. Before each renewal, we reach out so you decide when to reorder. You're never locked in.
Yes. Compounded combination therapy prescribed for weight management is an FSA/HSA-eligible expense when prescribed by a licensed physician. We provide an itemized receipt for reimbursement.
Once your physician approves your prescription (typically within 24 hours of intake), the compounding pharmacy ships within 2–3 business days via expedited carrier. Most patients receive their first dose within 5–7 days of completing intake.
One price for all dosages, covering physician care, medication, supplies and shipping — there is no separate $95 physician-care fee on this program.
The bundle price is the monthly figure on a 3-month term. The amount actually charged for the term is shown at checkout before you pay.
The price is flat across dosages; injection supplies and free expedited shipping are included.
Nothing is auto-billed and a refill is only charged after you confirm it.
Eligibility is decided by your physician and by your state's rules.
No claim is made that a combination works better than a single medication. The brand labels referenced elsewhere on this site do not recommend using two GLP-1 receptor agonists together, and nothing here should be read as label support for this schedule.
No. GOAL.MD does not auto-bill compounded medication programs. Nothing reorders by itself and your card is only charged after you tell us to proceed.
No. GOAL.MD is a cash-pay practice. We accept credit cards, FSA/HSA cards, and financing through Affirm, Afterpay and Klarna.
One monthly price covers the physician care, the compounded medication from a licensed U.S. pharmacy, injection supplies and free expedited shipping. There is no separate membership fee on compounded programs.
Your physician decides each step of your titration. The program price does not change with your dose.
Follow the storage instructions supplied by the compounding pharmacy with your specific preparation. Storage requirements differ between preparations, so use the document in your shipment rather than a general rule.
Speak to your physician before stopping. Because compounded programs are never auto-renewed, stopping simply means not confirming your next order.
Contact GOAL.MD support at customer@jellyfish.md with your order details and we will escalate with the pharmacy on your behalf. We do not guarantee a delivery date and we will not tell you a medication is still usable — if the condition of a shipment is in doubt, do not use it until your physician or the pharmacy has reviewed it. If delivery instructions you have received conflict, treat the prescribing information supplied with the medication as authoritative and ask us to confirm in writing.
This combination schedule was reviewed and approved by Dr. Michael Mimlitz, MD on September 14, 2026 as GOAL.MD clinical practice. It is not supported by any approved product label: current U.S. prescribing information for brand-name semaglutide and tirzepatide does not recommend coadministration with another GLP-1 receptor agonist, so no product label is cited here in support of it.
Compounded medications are prepared by licensed U.S. 503A/503B pharmacies. Compounded preparations are not FDA-approved.
GOAL.MD does not auto-bill compounded medication programs. Nothing reorders by itself and your card is only charged after you tell us to proceed.
GOAL.MD serves patients in all 50 US states. Which medication your physician can prescribe still depends on your state's rules, your medical evaluation, and pharmacy eligibility.
This records the last completed medical review of this page: Dr. Michael Mimlitz, MD, on September 14, 2026. Wording added or edited after that date has not been through a new review and is queued for one. Prices, manufacturer program terms and other non-clinical details are updated as the manufacturers publish them and are not part of any clinical review.
Last medical review: Dr. Michael Mimlitz, MD — September 14, 2026.
Questions? Call 314-907-3103 or toll-free 800-674-2855, Monday–Friday, 9am–5pm Central, or email customer@jellyfish.md.
Compounded semaglutide + tirzepatide, physician-prescribed: $547/mo on a 3-month bundle, $597/mo standard, flat for all dosages. Supplies and shipping included, never auto-billed.